Trending Now
- Tamilnadu player Mariappan Thangavelu creates history by winning a hat-trick of medals in the high jump event at the Paraolympics
- Actor Prabhas has donated ₹5 crore to the Chief Ministers’ Relief Fund to help flood-affected people of Andhra and Telangana
- Salary drawn is between Rs.200 crore – Rs.250 crore per film; selling tickets at 2000 instead of giving it for free to the fans, how can such a person work for the nation?”- Minister Anbarasan
- People of Wayanad have experienced disaster; they need our support to recover from unimaginable losses – Rahul Gandhi
Businesswire
Eurofins Announces Acquisition of Assets of Gomti Life Sciences
February 5, 2020
Business Wire IndiaEurofins, through Eurofins Advinus, acquires all assets of Gomti Life Sciences Private Limited through a Business Transfer Agreement. The assets include a fully equipped state-of-the-art manufacturing facility located in Bidadi Industrial Area, Bangalore, India, with cGMP pilot plant, intermediate area and ISO class 8 clean rooms and a total reactor capacity of about 45 KL.
With this acquisition, Eurofins Advinus will be able to manufacture RSMs, intermediates, APIs and NCEs. The company can now support drug substance requirements from multi kilogram to MT scale for Toxicology studies, clinical trials and launch quantities.
Rajiv Malik, MD of Eurofins Advinus Limited commented: This acquisition could be a game changer for Eurofins Advinus as it enables the group to enter clinical development and commercial supply part of the Pharma R&D value chain through cGMP API supplies of NCEs. This addition is also a part of a larger foray of the Eurofins group into CDMO / CRAMS market.
Source: Businesswire
With this acquisition, Eurofins Advinus will be able to manufacture RSMs, intermediates, APIs and NCEs. The company can now support drug substance requirements from multi kilogram to MT scale for Toxicology studies, clinical trials and launch quantities.
Rajiv Malik, MD of Eurofins Advinus Limited commented: This acquisition could be a game changer for Eurofins Advinus as it enables the group to enter clinical development and commercial supply part of the Pharma R&D value chain through cGMP API supplies of NCEs. This addition is also a part of a larger foray of the Eurofins group into CDMO / CRAMS market.
Source: Businesswire
